会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明授权
    • Method of sterilization and apparatus therefore
    • 因此灭菌方法和设备
    • US07892486B2
    • 2011-02-22
    • US10594387
    • 2005-03-29
    • Akira MizunoHiroyuki YuyamaYoshinori Shirahara
    • Akira MizunoHiroyuki YuyamaYoshinori Shirahara
    • A61L2/20
    • A61L2/208A61L2/14A61L2/202A61L2202/24
    • A harmless sterilization method and sterilization apparatus which provide adequate sterilization effects without residual gas. The method includes a sterilization step in which a chamber containing an object to be sterilized is depressurized; a hydrogen peroxide supply step in which hydrogen peroxide is supplied into the chamber; an ozone supply step in which ozone is supplied into the chamber; a sterilization step in which the hydrogen peroxide and ozone supplied inside the chamber are dispersed to sterilize the object to be sterilized; an exhaust step in which gas inside the chamber is exhausted; and a plasma generation step in which plasma is generated inside the chamber to break down hydrogen peroxide and ozone remaining near the object to be sterilized, and radicals which promote sterilization are generated.
    • 无残留气体提供充分杀菌效果的无害灭菌方法和杀菌装置。 该方法包括灭菌步骤,其中包含待消毒物体的室被减压; 过氧化氢供给步骤,其中将过氧化氢供给到室中; 将臭氧供给到所述室内的臭氧供给步骤; 灭菌步骤,其中分散在室内的过氧化氢和臭氧被分散以消毒待消毒的物体; 废气步骤,其中室内的气体被耗尽; 以及等离子体产生步骤,其中在腔室内产生等离子体以分解残留在待消毒物体附近的过氧化氢和臭氧,并产生促进灭菌的自由基。
    • 4. 发明授权
    • Axial gap rotating electrical machine
    • 轴向间隙旋转电机
    • US07187098B2
    • 2007-03-06
    • US11065176
    • 2005-02-24
    • Masahiro HasebeMasami IshikawaAkira Mizuno
    • Masahiro HasebeMasami IshikawaAkira Mizuno
    • H02K21/12
    • H02K21/24H02K1/2793
    • An axial gap rotating electrical machine is provided with permanent magnets and cores in a rotor. The permanent magnets are oriented such that magnetization surfaces face in the circumferential direction of the rotor. The cores are arranged alternately with the permanent magnets in the circumferential direction of the rotor. The amount of magnetic flux on the outside in the radial direction of the rotor is made greater than the amount of magnetic flux on the inside in the radial direction of the rotor. As a result, the magnetic flux density at the rotor cores can be made substantially constant in the radial direction of the rotor and torque output with respect to the size of the permanent magnets is improved by preventing magnetic saturation of the cores.
    • 轴向间隙旋转电机在转子中设置永磁体和铁心。 永磁体被定向为使得磁化表面在转子的圆周方向上面对。 芯与转子的圆周方向上的永久磁铁交替排列。 使转子的径向外侧的磁通量大于转子径向内侧的磁通量。 结果,转子芯的磁通密度可以在转子的径向方向上基本上恒定,并且通过防止磁芯的磁饱和来改善相对于永磁体的尺寸的扭矩输出。
    • 5. 发明申请
    • Flat type image display device
    • 平面型图像显示装置
    • US20060197721A1
    • 2006-09-07
    • US10548717
    • 2004-05-27
    • Akira MizunoMasayuki Esaki
    • Akira MizunoMasayuki Esaki
    • G09G3/28
    • H04N5/64H04N5/70Y10S345/901
    • A flat panel image display unit such as a plasma display device is provided having a structure of signal input terminals that is adaptable flexibly to a plurality of different kinds of video signals. The image display unit includes a flat display panel, a display drive circuit block, an input signal circuit block connected between the display drive circuit block and an external apparatus for outputting a video signal, and an enclosure for housing the above components. The input signal circuit block includes a plurality of different kinds of board blocks provided replaceably according to a plurality of different forms of signals. A casing member is placed inside the enclosure and is provided with an insertion opening for accepting insertion of any of the board blocks. A guide rail is for positioning the board block to a predetermined position. The plurality of guide rails are provided according to the board block of a smallest unit size.
    • 提供了诸如等离子体显示装置的平板图像显示单元,其具有可灵活地适应于多种不同种类的视频信号的信号输入端的结构。 图像显示单元包括平面显示面板,显示驱动电路块,连接在显示驱动电路块和用于输出视频信号的外部设备之间的输入信号电路块,以及用于容纳上述组件的外壳。 输入信号电路块包括根据多种不同形式的信号可替换地提供的多种不同种类的板块。 外壳部件放置在外壳的内部,并且设置有用于接受任何板块的插入的插入开口。 导轨用于将板块定位到预定位置。 根据最小单位尺寸的板块提供多个导轨。
    • 8. 发明授权
    • Pyrrolothiazine and pyrrolothiazepine compounds having serotonin-2 receptor antagonistic and alpha-1-blocking action
    • 具有5-羟色胺受体拮抗作用和α-1-阻断作用的吡罗噻嗪和吡咯并噻吩类化合物
    • US06624314B2
    • 2003-09-23
    • US09871655
    • 2001-06-04
    • Akira MizunoMakoto ShibataTomoe KameiHarukazu FukamiNorio Inomata
    • Akira MizunoMakoto ShibataTomoe KameiHarukazu FukamiNorio Inomata
    • C07D20736
    • C07D513/04C07D207/36
    • A pyrrolesulfonamide derivative having the following formula (I): wherein the ring P represented by  is a pyrrole ring having the following structure: wherein R represents alkyl, cycloalkyl, cycloalkylalkyl or aralkyl; the dashed line indicates the presence or absence of a bond; l stands for 0 or 1; A represents alkylene, alkenylene or alkynylene; and Y represents a group  in which W represents CH, C═ or N; m stands for 0 or 1 when W is CH or N, or m stands for 1 when W is C═; B represents a specific divalent group; E1 and E2 each independently represents H or lower alkyl; and D represents an aromatic hydrocarbon group or heterocyclic group. The compound (I) has strong serotonin-2 receptor antagonistic action and low toxicity and less side effects, and is useful as a therapeutic for circulatory diseases such as ischemic heart diseases, cerebrovascular disturbances and peripheral circulatory disturbances.
    • 具有下式(I)的吡咯磺酰胺衍生物:其中由具有以下结构的吡咯环表示的环P:其中R表示烷基,环烷基,环烷基烷基或芳烷基; 虚线表示存在或不存在键; l代表0或1; A表示亚烷基,亚烯基或亚炔基; Y表示W表示CH,C =或N的基团; 当W为CH或N时,m代表0或1,当W为C =时,m代表1; B表示特定的二价基团; E1和E2各自独立地表示H或低级烷基; D表示芳族烃基或杂环基。 化合物(I)具有强的5-羟色胺-2受体拮抗作用,毒性低,副作用小,作为循环系统疾病如缺血性心脏病,脑血管障碍和周围循环障碍的治疗有用。
    • 9. 发明授权
    • Pyrroloazepine compounds
    • 吡咯并氮化合物
    • US06187772B1
    • 2001-02-13
    • US09147248
    • 1998-11-12
    • Akira MizunoMakoto ShibataTomoe KameiNorio Inomata
    • Akira MizunoMakoto ShibataTomoe KameiNorio Inomata
    • C07D48704
    • C07D207/416C07D487/04
    • Disclosed are pyrroloazepine compounds and their salts. These pyrroloazepine compounds are represented by formula (I) wherein the dashed line indicates the presence or absence of a bond; and, when the bond is present, Z2 is not present and Z1 is H but, when the bond is absent, Z1 and Z2 are both Hs; Z1 is H and Z2 is OH; Z1 and Z2 are both SR5s in which R5 is alkyl, aralkyl or aryl; or Z1 and Z2 are combined together to represent O, NOR6 in which R6 is H, alkyl, aralkyl or aryl, or C2-C3 alkylenedithio; R is H, alkyl, cycloalkyl, cycloalkyl alkyl or aralkyl; and the ring P is a specific pyrrole ring. These pyrroloazepine compounds and salts are effective as preventives or therapeutics for general circulatory diseases such as hypertension, heart failure, ischemic hear diseases, cerebrovascular disturbances and peripheral circulatory disturbances. Their production processes are also disclosed
    • 公开了吡咯并氮化合物及其盐。 这些吡咯并氮化合物由式(I)表示,其中虚线表示存在或不存在键; 当存在键时,Z 2不存在且Z1为H,但不存在键时,Z 1和Z 2均为Hs; Z1是H,Z2是OH; Z 1和Z 2都是SR 5,其中R 5是烷基,芳烷基或芳基; 或Z 1和Z 2组合在一起以表示其中R 6为H,烷基,芳烷基或芳基或C 2 -C 3亚烷基二硫基的O,NOR 6; R为H,烷基,环烷基,环烷基烷基或芳烷基; 环P是特定的吡咯环。 这些吡咯并氮化合物和盐可用作一般循环系统疾病如高血压,心力衰竭,缺血性听觉疾病,脑血管障碍和外周循环障碍的预防剂或治疗剂。 他们的生产过程也被披露
    • 10. 发明授权
    • Pyrroloazepine derivatives
    • 吡咯并氮衍生物
    • US5962448A
    • 1999-10-05
    • US875495
    • 1997-08-21
    • Akira MizunoMakoto ShibataTomoe IwamoriTetsuo ShimamotoKyoko NakanishiNorio Inomata
    • Akira MizunoMakoto ShibataTomoe IwamoriTetsuo ShimamotoKyoko NakanishiNorio Inomata
    • A61P7/00A61P9/00C07D207/34C07D487/04C07D495/20A61K31/55
    • C07D487/04C07D207/34
    • A pyrroloazepine compound having the following formula (I): whereinthe ring P represented by ##STR1## is a pyrrole ring having the following structure: ##STR2## wherein R.sub.1 represents C.sub.1 -C.sub.8 alkyl, C.sub.3 -C.sub.8 cycloalkyl, C.sub.4 -C.sub.8 cycloalkyl-alkyl, C.sub.6 -C.sub.14 aryl or C.sub.7 -C.sub.22 aralkyl, which are optionally substituted; and R.sub.2 represents H or C.sub.1 -C.sub.8 alkyl, which is optionally substituted; the dashed line indicates the presence or absence of a bond; and, when the bond is present, Z.sub.2 is not present and Z.sub.1 represents H, but, when the bond is absent, Z.sub.1 and Z.sub.2 are both H; Z.sub.1 represents H and Z.sub.2 represents a group OR.sub.3, in which R.sub.3 represents H, C.sub.1 -C.sub.8 alkyl, or C.sub.7 -C.sub.22 aralkyl, which are optionally substituted; Z.sub.1 and Z.sub.2 both represent groups SR.sub.4, in which R.sub.4 represents C.sub.1 -C.sub.8 alkyl or C.sub.7 -C.sub.22 aralkyl, which are optionally substituted; or Z.sub.1 and Z.sub.2 are combined together to represent O, a group NOR.sub.5, in which R.sub.5 represents H, or C.sub.1 -C.sub.8 alkyl or C.sub.2 -C.sub.3 alkylenedithio, which are optionally substituted; A represents alkylene, alkenylene or alkynylene; and Y represents a group in which W is CH, C.dbd. or N, m is for 0 or 1, n is for 1, 2 or 3, G is O, S, C.dbd.O, sulfinyl, sulfonyl, alkylene, alkenylene or acetal; E.sub.1 and E.sub.2 is H or C.sub.1 -C.sub.8 alkyl; and D represents an aromatic hydrocarbon or an aromatic heterocyclic ring. The compound (I) has strong serotonin-2 receptor antagonistic action and low toxicity and less side effects, and is therapeutically useful in the treatment of circulatory diseases and/or conditions related thereto.
    • PCT No.PCT / JP96 / 03522 Sec。 371日期1997年8月21日 102(e)日期1997年8月21日PCT提交1996年12月2日PCT公布。 出版物WO97 / 20845 日期:1997年6月12日具有下式(I)的吡咯并氮吡啶化合物:其中由代表的环P是具有以下结构的吡咯环:其中R1表示C1-C8烷基,C3-C8环烷基,C4-C8环烷基 - 烷基 ,任选被取代的C 6 -C 14芳基或C 7 -C 22芳烷基; 并且R 2表示H或被任选取代的C 1 -C 8烷基; 虚线表示存在或不存在键; 当存在键时,Z 2不存在,Z1表示H,但不存在键时,Z 1和Z 2均为H; Z1表示H,Z2表示OR3,其中R3表示H,任选取代的C 1 -C 8烷基或C 7 -C 22芳烷基; Z 1和Z 2均表示SR 4,其中R 4表示任选取代的C 1 -C 8烷基或C 7 -C 22芳烷基; 或Z 1和Z 2组合在一起表示O,其中R 5表示H的基团NOR 5或任选被取代的C 1 -C 8烷基或C 2 -C 3亚烷基二硫基; A表示亚烷基,亚烯基或亚炔基; 并且Y表示W为CH,C =或N的基团,m为0或1,n为1,2或3,G为O,S,C = O,亚磺酰基,磺酰基,亚烷基,亚烯基或亚磺酰基 乙缩醛 E1和E2是H或C1-C8烷基; D表示芳族烃或芳香族杂环。 化合物(I)具有强的5-羟色胺-2受体拮抗作用和低毒性和较少的副作用,并且在治疗循环系统疾病和/或与之有关的病症中是治疗上有用的。